| Literature DB >> 34079548 |
Ziang Zhu1, Tong Li1, Jinya Chen1, Jai Kumar2, Princy Kumar2, Jing Qin3, Colleen Hadigan4, Irini Sereti4, Jason V Baker5, Marta Catalfamo1.
Abstract
Endothelial inflammation and damage are the main drivers of cardiovascular risk/disease. Endothelial repair is mediated in part by recruitment of bone marrow endothelial progenitor/endothelial colony forming cells (EPC/ECFC). People with HIV (PWH) have increased cardiovascular risk and the impact of infection in endothelial repair is not well defined. The low frequencies and challenges to in vitro isolation and differentiation of EPC/ECFC from PBMCs had made it difficult to study their role in this context. We hypothesized that HIV driven inflammation induces phenotypic changes that reflects the impact of infection. To test this hypothesis, we evaluated expression of markers of trafficking, endothelial differentiation, and angiogenesis, and study their association with biomarkers of inflammation in a cohort of PWH. In addition, we investigated the relationship of circulating endothelial progenitors and angiogenic T cells, a T cell subset with angiogenic function. Using a flow cytometry approach, we identified two subsets of circulating progenitors LIN4-CD45-CD34+ and LIN4-CD45dimCD34+ in PWH. We found that the phenotype but not frequencies were associated with biomarkers of inflammation. In addition, the percentage of LIN4-CD45dimCD34+ was associated with serum levels of lipids. This data may provide a new tool to better address the impact of HIV infection in endothelial inflammation and repair.Entities:
Keywords: HIV infection; T cell activation; endothelial inflammation; endothelial progenitor cells; endothelial repair
Mesh:
Substances:
Year: 2021 PMID: 34079548 PMCID: PMC8165313 DOI: 10.3389/fimmu.2021.663412
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Patient Characteristics.
| Patients (n = 36) | |
|---|---|
|
| 52 (45-57) |
|
| |
| male | 31 (86.1) |
| female | 5 (13.9) |
|
| |
| White | 24 (66.7) |
| African American | 2 (5.6) |
| Hispanic | 8 (22.2) |
| Other | 2 (5.6) |
|
| |
| Smoker, n (%) | 12 (33.3) |
| Diabetes, n (%) | 5 (13.8) |
| Hypertension diagnosis, n (%) | 11 (30.6) |
| Lipid-lowering therapy (%) | 12 (33.3) |
| Statins n (%) | 11 (30.6) |
| Aspirin n (%) | 10 (27.8) |
| BMI Kg/m2, median (IQR) | 27.03 (24.46, 32.62) |
| SBP mmHg, median (IQR) | 130 (121, 140.5) |
| DBP mmHg, median (IQR) | 79 (74, 83) |
| FRS 10 yr %, median (IQR) | 11.2 (9, 18.4) |
|
| 14 (10, 20) |
|
| |
| CD4 counts (cells/μL) | 662 (503, 856) |
| CD8 counts (cells/μL) | 557.5 (436.5-913.8) |
| CD4 nadir (cells/μL) | 331.5 (91.25, 404.5) |
| CD4/CD8 ratio | 1.03 (0.734, 1.58) |
|
| |
| Tenofovir | 24 (64) |
| Abacavir | 11 (30.6) |
| NNRTI | 11 (30.6) |
| PI | 13 (36.1) |
| INSTI | 17 (47.2) |
|
| |
| Total Cholesterol mg/dL | 184.5 (145,.5, 216.3) |
| LDL mg/dL | 108 (79, 129,3) |
| HDL mg/dL | 46 (34, 64.75) |
| Triglycerides mg/dL | 123.5 (85.75, 177.5) |
|
| |
| IL-8 (pg/mL) | 3.482 (2.718, 4.843) |
| hsIL-6 (pg/mL) | 1.806 (1.28, 2.527) |
| IL-6R (ng/mL) | 38.46 (31.69, 46.410) |
| TNFα (pg/mL) | 2.491 (1.896, 3.129) |
| TNFRI (ng/mL) | 2.784 (2.297, 3.1740) |
| hsCRP mg/mL | 1.223 (0.6645, 2.566) |
| sCD163 (mg/L) | 0.1769 (0.1414, 0.265) |
| sCD14 (mg/L) | 1.705 (1.561, 1.88) |
| D-dimer mg/L | 0.3512 (0.2362, 0.4547) |
| TFPI (ng/mL) | 31.2 (28.7, 37.13) |
| sICAM1 (µg/mL) | 332.2 (259.6, 407.7) |
| sVCAM1 (µg/mL) | 407.7 (360.1, 552.1) |
SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure, ART, antiretrovirals, FRS, Framingham Risk Score; DM, Diabetes Mellitus, BMI, Body mass index, LDL, Low-Density Lipoprotein cholesterol; HDL, High-Density Lipoprotein cholesterol; IL-8, interleukin 8; IL-6, interleukin 6; IL-6R, interleukin 6 Receptor; TNF, Tumor Necrosis Factor; TNFRI, Tumor Necrosis Factor Receptor I, hsCRP, high sensitivity C-Reactive Protein; sCD163, soluble CD163; sCD14, soluble CD14; TFPI ,Tissue Factor Pathway Inhibitor; sICAM1, soluble intercellular adhesion molecule1; sVMAC1, soluble vascular adhesion molecule1.
Figure 1Detection and phenotype of two circulating cell progenitors LIN4-CD45-CD34+ and LIN4-CD45dimCD34+ in PBMCs from PWH. PBMCs from PWH (n= 36) were thawed and rested overnight. PBMCs were stained with LIVE/DEAD followed by a cocktail of mAbs: LIN4, CD45, CD3, CD8, CD34, CD31,CD105, CD49f, CD133, CD146, PDL-1, CD14, CD309 and CD202b ( ). Full minus one (FMO) was used control. (A) Representative dot plots of the gating strategy. Frequency of: (B) LIN4-, (C) LIN4-CD45- and LIN4-CD45+, (D) LIN4-CD45-CD34+ and LIN4-CD45dimCD34+ cells are represented as the frequency of total live cells. (E) Expression of the markers CD31, CXCR4, CD49f, CD309, CD202b, CX3CR1, CD105, CD133, CD146 and PD-L1 in the LIN4-CD45-CD34+ (closed red circle) and LIN4-CD45dimCD34+ (open red circle) cells are shown as median fluorescence intensity (MFI). Whiskers represent median and IQR. Comparison between subsets was performed using non-parametric Wilcoxon test. P value < 0.05 was considered significant.
Figure 2Phenotype of circulating cell progenitors LIN4-CD45-CD34+ and LIN4-CD45dimCD34+ in PWH. PBMCs from healthy control (HC, n=10), PWH with viral loads < 50 copies/ml (n= 12), and > 50 copies/ml (n= 19) were thawed and rested overnight. PBMCs were stained with LIVE/DEAD followed by a cocktail of mAbs: LIN4, CD45, CD34, CD31, CXCR4, CD105, CD49f, CD133, CD146, PDL-1, CD309, CD117 and CD202b ( ). (A) Percentage of LIN4-, LIN4-CD45- and LIN4-CD45+(Left panel), and percentage of LIN4-CD45-CD34+ and LIN4-CD45dimCD34+ (Right panel). Percentages are represented as frequency of total live cells. Expression of the markers in: (B) LIN4-CD45-CD34+, and (C) LIN4-CD45dimCD34+ cells. Expression of the markers as shown as median fluorescence intensity (MFI). Whiskers represent median and IQR. Comparison between groups was performed using non-parametric Mann-Whitney test. P value < 0.05 was considered significant.
Figure 3Expression of CX3CR1+CD4 and CD8 Tang cells in PWH. PBMCs from PWH (n= 36) were thawed and rested overnight. PBMCS were stained with LIVE/DEAD followed by a cocktail of mAbs described in Table Flow Cytometry Panel ( ). CD4 T cells were gated as CD3+CD8- and CD8 T cells were gated as CD3+CD8+. (A) CD4 and CD8 angiogenic T cells (Tang) were identified based on surface expression of CXCR4+CD31+. Surface expression of CX3CR1 were analyzed in CD4 and CD8 Tang cells and full minus one (FMO) was used control. (B) Percentage CD4 and CD8 Tang cells. (C) Expression of CX3CR1 in CD4 and CD8 Tang cells expressed as frequency of the parent population. Comparison between CD4 and CD8 Tang cells was performed using nonparametric Wilcoxon test. P value < 0.05 was considered significant.